Century Therapeutics, Inc. IPSC 深 沪
等待开盘 10-07 09:30:00 美东时间
1.32
-0.160
-10.81%
华盛通- 最 高2.25
- 今 开1.48
- 成交量 270.77万股
- 最 低 1.29
- 昨 收 1.48
- 总市值 7.77万
- 52周最高 3.04
- 市盈率 静 --
- 换手率 4600.96%
- 52周最低 0.435
- 委 比 -22.63%
- 总股本 5.89万
- 历史最高 32.899
- 量 比 3.61
- 振 幅 64.86%
- 历史最低 0.3418
- 每 手 1
- 风险率 0.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Century Therapeutics Presents CNTY-813 Nonclinical Data At EASD 2026
Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1 diabetesCNTY-813 IND
10-02 20:07
Century Therapeutics Maintains $150M ATM Program, With $131.6M Remaining In Capacity
Other Events. On July 10, 2025, Century Therapeutics, Inc. (the "Company") filed with the Securities and Exchange Commission (the "SEC") a shelf registration statement on Form S-3 (File No. 333-288616), which became
03-27 04:45
从“跟跑”迈向“领跑”：CSGCT大会汇聚全球智慧，共筑细胞与基因治疗新生态
（来源：蚌埠新闻网） 转自：蚌埠新闻网 立足监管、汇聚智慧、链接全球、共创未来。中国细胞与基因治疗领域迎来年度顶级盛会。 2025年9月12日至13日，202...
2025-09-22 17:06
干细胞行业专家交流
（来源：纪要头等座） 1、间充质干细胞商业化进展与挑战 ·国内首款干细胞药商业化现状：国内首款干细胞药方面，博生卓越已启动商业化进程，首例病人在前几个月完成注射...
2025-07-31 18:18
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
Century Therapeutics will present two studies at the upcoming EULAR 2025 Congress in Barcelona, highlighting their iPSC-derived cell therapies for autoimmune diseases and cancer.
2025-05-28 20:01
Century Therapeutics Tapped Morgan Conn Of Pharvaris as CFO, Effective Oct 14
Century Therapeutics, Inc. (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced the
2024-09-26 19:07
